FDA and ESA Safety: A Conversation with Bob Temple and Ellis Unger
This article was originally published in RPM Report
Executive Summary
The cardiovascular risks associated with ESAs in the renal disease population are being reevaluated by FDA with the outcome of three clinical trials now in hand. The agency is considering a number of issues as it decides what to do with these therapies